Update on BioLineRx's BL-8040 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 5:10PM CDT
BioLineRx announced that Prof. Arnon Nagler was given the final regulatory approval to evaluate BL-8040 in a phase I/II study for the treatment of CML.
BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment
Business Wire - Thu Apr 10, 6:01AM CDT
BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study. BioLineRx is currently developing BL-8040 in a Phase 2 study for treating acute myeloid leukemia (AML), and in a Phase 1 study for stem cell mobilization, as a pre-treatment for stem cell transplantation. The Company has received orphan drug designation for both these indications.
IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day.
ChemoCentryx (CCXI) Jumps: Stock Rises 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:51AM CDT
ChemoCentryx, Inc. was a big mover last session, as its shares rose nearly 10% on the day.
BioLineRx Reports Narrower 2013 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 9:20AM CDT
BioLineRx reported full year 2013 loss of 8 cents per share, narrower than the 2012 loss of 12 cents per share.
BioLineRx Reports Year End 2013 Financial Results
Business Wire - Mon Mar 17, 7:02AM CDT
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2013.
BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 in Immunotherapy
Business Wire - Fri Mar 14, 6:00AM CDT
--- Top-line results from both trials expected in next 9-12 months -
Pipeline Update at BioLineRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:50PM CDT
BioLineRx announced the successful completion of the single administration, dose-escalation stage of the ongoing phase I/II study on BL-7010
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.
BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014
Business Wire - Tue Mar 11, 6:01AM CDT
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014, before the U.S. markets open.
BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment
Business Wire - Mon Mar 10, 6:00AM CDT
--BL-7010 now advancing to repeated administration part of study; results expected mid 2014
BioLineRx Closes $24.1 Million Underwritten Public Offering of its American Depositary Shares
Business Wire - Fri Mar 07, 11:00AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public offering of 9,660,000 American Depositary Shares ("ADSs"
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
Portola Pharmaceuticals (PTLA) Jumps: Stock Up 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:51AM CST
Portola Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 8% on the day.
BioLineRx to Present at the Annual ROTH Growth Stock Conference in California
Business Wire - Wed Mar 05, 6:03AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 26th Annual ROTH Growth Stock Conference being held at the Ritz Carlton in Dana Point, CA.
Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:39AM CST
Nektar Therapeutics was a big mover last session, as its shares rose nearly 11% on the day.
BioLineRx Prices $21.0 Million Underwritten Public Offering of its American Depositary Shares
Business Wire - Tue Mar 04, 8:07AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has priced an underwritten public offering of 8,400,000 American Depositary Shares ("ADSs"
Can Auxilium Pharma (AUXL) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:30AM CST
Auxilium Pharma has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy.
BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
PR Newswire - Mon Mar 03, 3:35PM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has commenced an underwritten public offering of its American Depositary Shares ("ADSs"
BioLineRx appoints Dr Sandra Panem to board
M2 - Tue Feb 25, 5:59AM CST
Biopharmaceutical company BioLineRx (NASDAQ:BLRX)(TASE:BLRX), headquartered in Israel, revealed on Monday the addition of Dr Sandra Panem PhD to its board of directors.